AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34048966 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model applied to validation cohort
Number of subjects: 9774
Study 34606166 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical, diversified nursing soft skills training
Number of subjects: 124
Study 34606166 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing training
Number of subjects: 124
Study 33338070 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous interaction context (storytime session)
Number of subjects: 43
Study 33338070 — intervention group
Group type: COMPARATOR
Intervention: Nonspontaneous interaction context (assistant bouncing infant in synchrony with a stranger)
Number of subjects: 43
Study 36382431 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal midazolam (0.3 mg/kg, max 15 mg)
Number of subjects: 84
Study 36382431 — intervention group
Group type: COMPARATOR
Intervention: Routine practice with no sedation
Number of subjects: 84
Study 32133486 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention group
Number of subjects: 63
Study 32133486 — intervention group
Group type: COMPARATOR
Intervention: Non-retention group
Number of subjects: 63
Study 34300168 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 1 (nicotine)
Number of subjects: 926
Study 34300168 — intervention group
Group type: COMPARATOR
Intervention: Version 2 (nicotine, on its own)
Number of subjects: 926
Study 36335684 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (5 mg/day)
Number of subjects: 451
Study 36335684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 34254233 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 448
Study 34254233 — intervention group
Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 448
Study 35241135 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (1 mg every 12 hours, increased to every 8 hours or every 6 hours depending on response)
Number of subjects: 80
Study 35241135 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 80
Study 35241135 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 80
Study 32551853 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 maintenance therapy
Number of subjects: 89
Study 32551853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 33136254 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Intervention
Number of subjects: 78
Study 33136254 — intervention group
Group type: COMPARATOR
Intervention: Caregiver‐assisted Intervention
Number of subjects: 78
Study 33136254 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 78
Study 33899682 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐ vs. other‐oriented benefits
Number of subjects: 521
Study 33899682 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐ vs. long‐term benefits
Number of subjects: 521
Study 33899682 — intervention group
Group type: EXPERIMENTAL
Intervention: Acknowledgment of disadvantages: yes vs. no
Number of subjects: 521
Study 33899682 — intervention group
Group type: COMPARATOR
Intervention: No-message control condition
Number of subjects: 521
Study 36418088 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (SSNB) with glenohumeral joint (GHJ) injection and physiotherapy
Number of subjects: 54
Study 36418088 — intervention group
Group type: COMPARATOR
Intervention: Placebo with glenohumeral joint (GHJ) injection and physiotherapy
Number of subjects: 54
Study 33272319 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet continuous positive airway pressure (CPAP)
Number of subjects: 120
Study 33272319 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 120
Study 34303786 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients (vitamins/minerals)
Number of subjects: 135
Study 34303786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 32882100 — intervention group
Group type: EXPERIMENTAL
Intervention: PD01A
Number of subjects: 30
Study 32882100 — intervention group
Group type: EXPERIMENTAL
Intervention: PD03A
Number of subjects: 30
Study 32882100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34585554 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT)
Number of subjects: 333
Study 34585554 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statin therapy
Number of subjects: 333
Study 34585554 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C < 70 mg/dl
Number of subjects: 333
Study 34585554 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure < 140 mm Hg
Number of subjects: 333
Study 34585554 — intervention group
Group type: EXPERIMENTAL
Intervention: Not smoking
Number of subjects: 333
Study 34585554 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 333
Study 34585554 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI / ARB therapy
Number of subjects: 333
Study 34585554 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 333
Study 34330312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellagic acid (200 mg per day)
Number of subjects: 60
Study 34330312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33034419 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (RA)
Number of subjects: 71
Study 33034419 — intervention group
Group type: COMPARATOR
Intervention: Cutting balloon angioplasty (CBA)
Number of subjects: 71
Study 33034419 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RA and CBA
Number of subjects: 71
Study 35255819 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy plus S. boulardii (Group S)
Number of subjects: 156
Study 35255819 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy plus L. reuteri (Group P)
Number of subjects: 156
Study 35255819 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 156
Study 35255819 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (S. boulardii)
Number of subjects: 156
Study 34334635 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated machine perfusion (HOPE)
Number of subjects: 46
Study 34334635 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage (SCS)
Number of subjects: 46
Study 33039810 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea cream
Number of subjects: 288
Study 33039810 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 288
Study 36201678 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention emphasizing evidence-based harm reduction and treatment programs
Number of subjects: 284
Study 36201678 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 284
Study 34292261 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based high-intensity interval exercise (TMHIIE)
Number of subjects: 12
Study 34292261 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometer high-intensity interval exercise (CEHIIE)
Number of subjects: 12
Study 34292261 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill moderate-intensity continuous exercise (TMMICE)
Number of subjects: 12
Study 34292261 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometer moderate-intensity continuous exercise (CEMICE)
Number of subjects: 12
Study 35691460 — intervention group
Group type: EXPERIMENTAL
Intervention: PBRM (15 mg/kg orally by gavage)
Number of subjects: 5
Study 35691460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 33890242 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 10743
Study 33890242 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin followed by warfarin
Number of subjects: 10743
Study 32075571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular alteplase
Number of subjects: 46
Study 32075571 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 46
Study 32075571 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intraventricular hemorrhage patients (combined treatment groups)
Number of subjects: 46
Study 32075571 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intraventricular hemorrhage patients
Number of subjects: 46
Study 33387347 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) applied biannually
Number of subjects: 79
Study 33387347 — intervention group
Group type: COMPARATOR
Intervention: Alternative restorative technique (ART)
Number of subjects: 79
Study 33387347 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF)
Number of subjects: 79
Study 32428974 — intervention group
Group type: EXPERIMENTAL
Intervention: Shigellosis (Shigella species)
Number of subjects: 192
Study 32428974 — intervention group
Group type: EXPERIMENTAL
Intervention: S. flexneri
Number of subjects: 192
Study 32428974 — intervention group
Group type: EXPERIMENTAL
Intervention: S. flexneri 6
Number of subjects: 192
Study 32428974 — intervention group
Group type: EXPERIMENTAL
Intervention: S. sonnei
Number of subjects: 192
Study 32428974 — intervention group
Group type: EXPERIMENTAL
Intervention: Norovirus
Number of subjects: 192
Study 32428974 — intervention group
Group type: EXPERIMENTAL
Intervention: Fever
Number of subjects: 192
Study 32428974 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of consciousness
Number of subjects: 192
Study 32428974 — intervention group
Group type: EXPERIMENTAL
Intervention: WHZ at enrollment
Number of subjects: 192
Study 32428974 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up anthropometrics
Number of subjects: 192
Study 35785538 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA air cleaners
Number of subjects: 0
Study 35785538 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon filter air cleaners
Number of subjects: 0
Study 35785538 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34407025 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga therapy (asanas and pranayama) from 18 to 22 weeks of gestation until delivery
Number of subjects: 0
Study 34407025 — intervention group
Group type: COMPARATOR
Intervention: Routine standard care
Number of subjects: 0
Study 32759258 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg two times per day
Number of subjects: 576
Study 32759258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 576
Study 35180569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program (medication review, health education, adherence aids, seizure registration, therapeutic drug monitoring)
Number of subjects: 182
Study 35180569 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study 35180569 — intervention group
Group type: COMPARATOR
Intervention: Pharmaceutical care program vs. Usual care
Number of subjects: 182
Study 34976813 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent sodium cantharidinate (SCA)
Number of subjects: 148
Study 34976813 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent docetaxel (DOX)
Number of subjects: 148
Study 34976813 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel/sodium cantharidinate combination (CON)
Number of subjects: 148
Study 34976813 — intervention group
Group type: COMPARATOR
Intervention: Control group (single-agent SCA and single-agent DOX)
Number of subjects: 148
Study 32168176 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric exercise
Number of subjects: 23
Study 32168176 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 23
Study 32168176 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg extension exercise
Number of subjects: 23
Study 32168176 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric peak torque
Number of subjects: 23
Study 32168176 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle soreness
Number of subjects: 23
Study 35669097 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA‐IM
Number of subjects: 2911
Study 35669097 — intervention group
Group type: COMPARATOR
Intervention: NET‐EN
Number of subjects: 2911
Study 35844809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual sufentanil 30 mcg
Number of subjects: 75
Study 35844809 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl 50 mcg
Number of subjects: 75
Study 32614201 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive outreach
Number of subjects: 1938
Study 32614201 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1938
Study 35982781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on 7 independent risk factors (age, diabetes history, gallbladder wall thickness, gallstone diameter, coexisting common bile duct stones, direct bilirubin, white blood cell count)
Number of subjects: 816
Study 35982781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram in validation cohort
Number of subjects: 816
Study 35982781 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration curve
Number of subjects: 816
Study 35982781 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision curve analysis (DCA) and clinical impact curve (CIC)
Number of subjects: 816
Study 32756180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF), 24 hours continuous treatment, n = 21
Number of subjects: 42
Study 32756180 — intervention group
Group type: COMPARATOR
Intervention: Control group (without HVHF), n = 21
Number of subjects: 42
Study 32756180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 42
Study 32756180 — intervention group
Group type: COMPARATOR
Intervention: Non-survival group
Number of subjects: 42
Study 32756180 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute physiology and chronic health evaluation I score and IL-6 level
Number of subjects: 42
Study 34965499 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enhanced diet using mealworms
Number of subjects: 216
Study 34965499 — intervention group
Group type: COMPARATOR
Intervention: Grain powder (control)
Number of subjects: 216
Study 34181876 — intervention group
Group type: COMPARATOR
Intervention: Baseline FeNO <25 ppb (n=291)
Number of subjects: 620
Study 34181876 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FeNO 25 to <50 ppb (n=185)
Number of subjects: 620
Study 34181876 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FeNO ≥50 ppb (n=144)
Number of subjects: 620
Study 34181876 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FeNO ≥25 ppb and blood eosinophil count ≥150 cells per μL and two or more prior exacerbations (n=157)
Number of subjects: 620
Study 35969887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose 17β estradiol (n = 72)
Number of subjects: 171
Study 35969887 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 99)
Number of subjects: 171
Study 34117493 — intervention group
Group type: EXPERIMENTAL
Intervention: Informatics intervention for IDH prevention
Number of subjects: 45
Study 34117493 — intervention group
Group type: EXPERIMENTAL
Intervention: Design principles for informatics intervention
Number of subjects: 45
Study 34117493 — intervention group
Group type: COMPARATOR
Intervention: Pragmatic cluster-randomized controlled trial
Number of subjects: 45
Study 35550053 — intervention group
Group type: EXPERIMENTAL
Intervention: Once‐only colonoscopy
Number of subjects: 0
Study 35550053 — intervention group
Group type: COMPARATOR
Intervention: Two rounds of faecal immunochemical testing 2 years apart
Number of subjects: 0
Study 32103495 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) after periodontal debridement (TG1)
Number of subjects: 75
Study 32103495 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) before periodontal debridement (TG2)
Number of subjects: 75
Study 32103495 — intervention group
Group type: COMPARATOR
Intervention: Placebo and periodontal debridement (CG)
Number of subjects: 75
Study 33389135 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride (salt) water-based mouth rinse (test group)
Number of subjects: 47
Study 33389135 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine mouth rinse (control group)
Number of subjects: 47
Study 33201927 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfers (UCTs) + package of community activities
Number of subjects: 2658
Study 36106652 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin icodec (once-weekly basal insulin)
Number of subjects: 0
Study 36106652 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100 or U300 or insulin degludec (comparator treatments)
Number of subjects: 0
Study 36106652 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Number of subjects: 0
Study 36106652 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100 or U300 or insulin degludec
Number of subjects: 0
Study 33464335 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy alone
Number of subjects: 234
Study 33464335 — intervention group
Group type: COMPARATOR
Intervention: Intravenous alteplase plus endovascular thrombectomy
Number of subjects: 234
Study 32383767 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic capsules containing Lactobacillus paracasei LPC‐S01 (24 billion CFU)
Number of subjects: 40
Study 32383767 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 40
Study 34877254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bo's abdominal acupuncture (BAA) combined with rehabilitation training (RT)
Number of subjects: 50
Study 34877254 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation training (RT)
Number of subjects: 50
Study 35410411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec F (CF)
Number of subjects: 20
Study 35410411 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 20
Study 35410411 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphate (DP)
Number of subjects: 20
Study 32712606 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (4 sessions over 4-6 weeks)
Number of subjects: 48
Study 32712606 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 48
Study 32718555 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Revascularization (CR)
Number of subjects: 1276
Study 32718555 — intervention group
Group type: COMPARATOR
Intervention: Incomplete Revascularization (IR)
Number of subjects: 1276
Study 36482786 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg acetaminophen
Number of subjects: 6
Study 36482786 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg acetaminophen
Number of subjects: 6
Study 36482786 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg acetaminophen
Number of subjects: 6
Study 36482786 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematology and biochemistry profiles
Number of subjects: 6
Study 34001849 — intervention group
Group type: EXPERIMENTAL
Intervention: meplazumab
Number of subjects: 59
Study 32469182 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (6.4 mg/kg every 3 weeks)
Number of subjects: 187
Study 32469182 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (physician's choice, 55 received irinotecan and 7 paclitaxel)
Number of subjects: 187
Study 32469182 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 187
Study 32469182 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 187
Study 35272017 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (100,000 IU monthly)
Number of subjects: 779
Study 35272017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 779
Study 33887451 — intervention group
Group type: EXPERIMENTAL
Intervention: CIED-derived patient activity (highest quintile, Q5)
Number of subjects: 1500
Study 33887451 — intervention group
Group type: EXPERIMENTAL
Intervention: CIED-derived patient activity (lowest quintile, Q1)
Number of subjects: 1500
Study 32620335 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (1 × 10^9 CFU/day, 2 capsules, tid) for 2 months
Number of subjects: 116
Study 32620335 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 116
Study 33926511 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA)
Number of subjects: 48
Study 33926511 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 48
Study 33926511 — intervention group
Group type: COMPARATOR
Intervention: Healthy Control (HC)
Number of subjects: 48
Study 32102507 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological noninvasive screening and treatment for atrophic gastritis
Number of subjects: 2847
Study 32102507 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive serologic screening
Number of subjects: 2847
Study 32102507 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology tests and noninvasive serologic screening
Number of subjects: 2847
Study 36244364 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam (0.2 mg/kg for infants 5 months to 2 years, adjusted for younger infants)
Number of subjects: 41
Study 36244364 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 41
Study 33775110 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior HF hospitalization within 12 months
Number of subjects: 4205
Study 33775110 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior HF hospitalization 0-4 months before index hospitalization
Number of subjects: 4205
Study 33775110 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior HF hospitalization 4-8 months before index hospitalization
Number of subjects: 4205
Study 33775110 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior HF hospitalization 8-12 months before index hospitalization
Number of subjects: 4205
Study 33775110 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior HF hospitalization more than 12 months before index hospitalization
Number of subjects: 4205